Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6490) 6490
Newspaper Article (663) 663
Book Chapter (243) 243
Newsletter (195) 195
Magazine Article (21) 21
Report (21) 21
Government Document (15) 15
Transcript (11) 11
Trade Publication Article (6) 6
Book Review (4) 4
Book / eBook (3) 3
Reference (3) 3
Publication (2) 2
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5114) 5114
life sciences & biomedicine (4639) 4639
vaccines (4113) 4113
humans (4065) 4065
animals (2850) 2850
immunology (2652) 2652
female (1811) 1811
vaccination (1601) 1601
antigens (1450) 1450
biological and medical sciences (1342) 1342
male (1327) 1327
vaccines, synthetic - immunology (1261) 1261
immunotherapy (1207) 1207
proteins (1197) 1197
infectious diseases (1182) 1182
medicine, research & experimental (1182) 1182
research & experimental medicine (1181) 1181
microbiology (1170) 1170
vaccine (1094) 1094
mice (1076) 1076
immunization (949) 949
immune response (934) 934
health aspects (921) 921
adult (918) 918
clinical trials (914) 914
vaccines, synthetic - adverse effects (845) 845
research (829) 829
viruses (822) 822
fundamental and applied biological sciences. psychology (815) 815
infections (810) 810
immune system (795) 795
cancer (793) 793
medical research (792) 792
medical sciences (785) 785
antibodies (717) 717
virology (691) 691
vaccines, synthetic - administration & dosage (688) 688
vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (682) 682
middle aged (660) 660
peptides (626) 626
review (586) 586
allergy and immunology (582) 582
immunogenicity (569) 569
medicine (557) 557
oncology (545) 545
lymphocytes (541) 541
biotechnology & applied microbiology (520) 520
t cells (510) 510
care and treatment (505) 505
analysis (502) 502
coronaviruses (500) 500
covid-19 (498) 498
tumors (485) 485
applied microbiology (482) 482
science & technology - other topics (477) 477
cancer vaccines - immunology (455) 455
prevention (454) 454
adolescent (450) 450
research article (447) 447
studies (446) 446
influenza (433) 433
cancer vaccines (431) 431
mice, inbred balb c (427) 427
lymphocytes t (420) 420
clinical trials as topic (417) 417
deoxyribonucleic acid--dna (417) 417
cytokines (415) 415
pharmacology & pharmacy (414) 414
multidisciplinary sciences (403) 403
dendritic cells (398) 398
immunity (398) 398
adjuvants, immunologic - administration & dosage (393) 393
cancer vaccines - therapeutic use (393) 393
enzyme-linked immunosorbent assay (373) 373
vaccines, synthetic - genetics (370) 370
treatment outcome (358) 358
public health (348) 348
viral diseases (345) 345
adjuvants (343) 343
medicine, experimental (341) 341
safety (339) 339
immunotherapy - methods (336) 336
abridged index medicus (333) 333
viral vaccines - immunology (331) 331
disease models, animal (329) 329
aged (320) 320
t-lymphocytes - immunology (318) 318
miscellaneous (317) 317
antibodies, viral - blood (313) 313
science (310) 310
pandemics (309) 309
adjuvant (304) 304
malaria (304) 304
vaccines, dna - immunology (284) 284
immunoglobulins (281) 281
vaccines - immunology (281) 281
vaccination - methods (280) 280
dendritic cells - immunology (279) 279
drug therapy (279) 279
virus diseases (277) 277
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7618) 7618
Russian (39) 39
Spanish (13) 13
Chinese (12) 12
French (12) 12
Portuguese (10) 10
Japanese (9) 9
German (8) 8
Italian (5) 5
Polish (5) 5
Korean (2) 2
Croatian (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Vaccine technologies: From whole organisms to rationally designed protein assemblies
by Karch, Christopher P and Burkhard, Peter
Biochemical pharmacology, ISSN 0006-2952, 11/2016, Volume 120, pp. 1 - 14
Nanoparticles | Vaccine | SAPN | Adjuvant | Rationally designed | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Recombinant Proteins - therapeutic use | Veterinary Drugs - adverse effects | History, 21st Century | Nanoparticles - chemistry | Humans | Vaccines, Synthetic - immunology | Antigens - therapeutic use | Vaccines - chemistry | Allergy and Immunology - history | Nanoparticles - therapeutic use | Vaccines, Subunit - adverse effects | Biopharmaceutics - history | Adjuvants, Immunologic - therapeutic use | Communicable Diseases - veterinary | Chemistry, Pharmaceutical - trends | Vaccines, Synthetic - chemistry | History, 20th Century | Recombinant Proteins - chemistry | Veterinary Drugs - immunology | Protein Engineering - trends | Antigens - chemistry | Communicable Disease Control - trends | Biopharmaceutics - methods | Drug Delivery Systems - trends | Protein Engineering - veterinary | Drug Delivery Systems - adverse effects | Veterinary Drugs - chemistry | Veterinary Drugs - therapeutic use | Drug Delivery Systems - veterinary | Nanoparticles - adverse effects | Recombinant Proteins - adverse effects | Vaccines - therapeutic use | Adjuvants, Immunologic - adverse effects | Antigens - adverse effects | Vaccines, Subunit - therapeutic use | Vaccines, Synthetic - adverse effects | Adjuvants, Immunologic - chemistry | Allergy and Immunology - trends | Drug Design | Chemistry, Pharmaceutical - history | Communicable Disease Control - history | Vaccines, Subunit - chemistry | Biopharmaceutics - trends | Vaccines - immunology | Vaccines, Synthetic - therapeutic use | Vaccines, Subunit - immunology | Protein Folding | Vaccines - adverse effects | Animals | Recombinant Proteins - immunology | Communicable Diseases - immunology | Antigens - immunology | History, 19th Century | Vaccines | Index Medicus | Rationally Designed
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
by Bernstein, David I and Munoz, Flor M and Callahan, S. Todd and Rupp, Richard and Wootton, Susan H and Edwards, Kathryn M and Turley, Christine B and Stanberry, Lawrence R and Patel, Shital M and Mcneal, Monica M and Pichon, Sylvie and Amegashie, Cyrille and Bellamy, Abbie R
Vaccine, ISSN 0264-410X, 2015, Volume 34, Issue 3, pp. 313 - 319
Allergy and Immunology | Cytomegalovirus | Vaccine | CMV gB | Adolescent | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Cytomegalovirus Vaccines - adverse effects | Adjuvants, Immunologic - administration & dosage | Vaccines, Subunit - genetics | Humans | DNA, Viral - analysis | Cytomegalovirus Infections - immunology | Vaccines, Synthetic - immunology | Cytomegalovirus Vaccines - administration & dosage | Antibodies, Viral - blood | Drug-Related Side Effects and Adverse Reactions - pathology | Adjuvants, Immunologic - adverse effects | Cytomegalovirus Infections - prevention & control | Vaccines, Synthetic - adverse effects | Blood - virology | Polymerase Chain Reaction | Polysorbates - administration & dosage | Female | Immunization Schedule | Vaccines, Subunit - adverse effects | Child | Cytomegalovirus Vaccines - genetics | Placebos - administration & dosage | Antigens, Viral - analysis | Polysorbates - adverse effects | Viral Envelope Proteins - genetics | Double-Blind Method | Vaccines, Synthetic - genetics | Squalene - administration & dosage | Urine - virology | Vaccines, Subunit - immunology | Squalene - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Vaccines, Subunit - administration & dosage | Viral Envelope Proteins - immunology | Vaccines, Synthetic - administration & dosage | DNA, Viral - genetics | Cytomegalovirus Vaccines - immunology | Clinical trials | Medical colleges | Vaccines | Teenage girls | Antigens | Cytomegalovirus infections | Vaccination | Urine | Confidence intervals | Substance abuse treatment | Consent | Hispanic Americans | Population | Infections | Index Medicus | adolescent | vaccine | cytomegalovirus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
by Glenn, Gregory M and Smith, Gale and Fries, Louis and Raghunandan, Rama and Lu, Hanxin and Zhou, Bin and Thomas, D. Nigel and Hickman, Somia P and Kpamegan, Eloi and Boddapati, Sarathi and Piedra, Pedro A
Vaccine, ISSN 0264-410X, 2012, Volume 31, Issue 3, pp. 524 - 532
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) | Microbiology | Applied microbiology | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
by Huttner, Angela, MD and Dayer, Julie-Anne, MD and Yerly, Sabine, MSc and Combescure, Christophe, PhD and Auderset, Floriane, PhD and Desmeules, Jules, Prof and Eickmann, Markus, PhD and Finckh, Axel, Prof and Goncalves, Ana Rita, PhD and Hooper, Jay W, PhD and Kaya, Gürkan, MD and Krähling, Verena, PhD and Kwilas, Steve, PhD and Lemaître, Barbara, MSc and Matthey, Alain, MD and Silvera, Peter, PhD and Becker, Stephan, Prof and Fast, Patricia E, MD and Moorthy, Vasee, MD and Kieny, Marie Paule, PhD and Kaiser, Laurent, Prof and Siegrist, Claire-Anne, Prof and VSV-Ebola Consortium and VSV Ebola Consortium
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 10, pp. 1156 - 1166
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Hemorrhagic Fever, Ebola - prevention & control | Vasculitis - epidemiology | Arthritis - epidemiology | Humans | Middle Aged | Vasculitis - pathology | Antigens, Viral - genetics | Male | Vaccination - adverse effects | Vaccines, Synthetic - immunology | Ebolavirus - genetics | Antibodies, Viral - blood | Dermatitis - epidemiology | Drug Carriers | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Arthritis - chemically induced | Vaccination - methods | Vaccines, Synthetic - adverse effects | Vesiculovirus - genetics | Adult | Ebola Vaccines - immunology | Female | Vasculitis - chemically induced | Placebos - administration & dosage | Double-Blind Method | Arthritis - pathology | Ebola Vaccines - administration & dosage | Ebola Vaccines - adverse effects | Switzerland | Drug-Related Side Effects and Adverse Reactions - epidemiology | Dermatitis - pathology | Adolescent | Aged | Vaccines, Synthetic - administration & dosage | Ebola virus | Hospitals | Clinical trials | Product development | Cross infection | Vaccines | Nosocomial infections | Health aspects | Epidemics | Disease | Arthritis | Dermatitis | Ankle | Wrist | Consortia | Pain | Adenoviruses | Fingers & toes | Skin | Public health | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
by Guy, Bruno and Barrere, Beatrice and Malinowski, Claire and Saville, Melanie and Teyssou, Remy and Lang, Jean
Vaccine, ISSN 0264-410X, 2011, Volume 29, Issue 42, pp. 7229 - 7241
Allergy and Immunology | Human | Development | Vaccine | Safety | Immunogenicity | Dengue | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Immunization, Secondary - adverse effects | Humans | Vaccination - adverse effects | Vaccines, Synthetic - immunology | Dengue Vaccines - genetics | Clinical Trials, Phase III as Topic | Animal Experimentation | Vaccination - methods | Dengue Virus - immunology | Vaccines, Synthetic - adverse effects | France | Yellow Fever Vaccine - adverse effects | Yellow Fever Vaccine - immunology | Vaccines, Synthetic - genetics | Immunization, Secondary - methods | Drug Discovery | Dengue - prevention & control | Dengue Vaccines - immunology | Dengue Virus - genetics | Vaccines, Attenuated - immunology | Yellow Fever Vaccine - genetics | Animals | Dengue Vaccines - adverse effects | Vaccines, Attenuated - adverse effects | Vaccines, Attenuated - genetics | Medical research | Dendritic cells | Vaccination | Medicine, Experimental | Clinical trials | Vaccines | Studies | Industrial development | Cell culture | Dengue fever | Technological change | Viruses | RNA polymerase | Tropical diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults
by Schmidt, Clint S and White, C. Jo and Ibrahim, Ashraf S and Filler, Scott G and Fu, Yue and Yeaman, Michael R and Edwards Jr., John E and Hennessey Jr., John P
Vaccine, ISSN 0264-410X, 2012, Volume 30, Issue 52, pp. 7594 - 7600
Allergy and Immunology | Vaccine | Als3p | Phase 1 | Candida | First-in-human | Staphylococcus aureus | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Adjuvants, Immunologic - administration & dosage | Fungal Vaccines - adverse effects | Immunoglobulin G - blood | Humans | Fungal Vaccines - genetics | Fungal Vaccines - immunology | Vaccines, Synthetic - immunology | Adjuvants, Immunologic - adverse effects | Candida albicans - genetics | Fungal Vaccines - administration & dosage | Vaccines, Synthetic - adverse effects | Leukocytes, Mononuclear - immunology | Staphylococcal Vaccines - adverse effects | Adult | Staphylococcal Vaccines - immunology | Alum Compounds - adverse effects | Placebos - administration & dosage | Staphylococcus aureus - genetics | Interleukin-17 - secretion | Interferon-gamma - secretion | Vaccines, Synthetic - genetics | Antibodies, Fungal - blood | Staphylococcal Vaccines - administration & dosage | Candida albicans - immunology | B-Lymphocytes - immunology | Staphylococcal Vaccines - genetics | Immunoglobulin A - blood | Staphylococcus aureus - immunology | T-Lymphocytes - immunology | Vaccines, Synthetic - administration & dosage | Alum Compounds - administration & dosage | Adults | Immune response | Vaccines | T cells | Index Medicus | vaccine | phase 1 | first-in-human
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights